Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACXP Acurx Pharmaceuticals, LLC*

Post-Mkt 12-24 13:49:52 EST

3.46

-0.04

-1.14%

盘后3.46

+0.000.00%

13:10 EST

High3.53	Low3.45	Vol11.83K
Open3.50	D1 Closing3.50	Amplitude2.29%
Mkt Cap7.20M	Tradable Cap6.26M	Total Shares2.08M
T/O41.08K	T/O Rate0.65%	Tradable Shares1.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACXP","market":"US","secType":"STK","nameCN":"Acurx Pharmaceuticals, LLC*","latestPrice":3.46,"timestamp":1766599199999,"preClose":3.5,"halted":0,"volume":11826,"hourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.46,"latestTime":"13:10 EST","volume":22,"amount":76.12,"timestamp":1766599804197},"delay":0,"floatShares":1808200,"shares":2081300,"eps":-10.366422,"marketStatus":"Post-Mkt","change":-0.04,"latestTime":"12-24 13:49:52 EST","open":3.5,"high":3.53,"low":3.45,"amount":41076.139845599995,"amplitude":0.022857,"askPrice":3.51,"askSize":22,"bidPrice":3.43,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-10.366422,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766613600000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.5,"preHourTrading":{"tag":"盘前","latestPrice":3.58,"preClose":3.5,"latestTime":"08:02 EST","volume":28,"amount":98.3999968,"timestamp":1766581332590},"postHourTrading":{"tag":"盘后","latestPrice":3.46,"preClose":3.46,"latestTime":"13:10 EST","volume":22,"amount":76.12,"timestamp":1766599804197},"volumeRatio":0.445402,"impliedVol":1.1448,"impliedVolPercentile":0.7483},"requestUrl":"/m/hq/s/ACXP","defaultTab":"news","newsList":[{"id":"2584372809","title":"Acurx Pharmaceuticals and Leiden University Medical Center Secure $375,000 Health~Holland Grant for Antibiotic Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2584372809","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584372809?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763471020,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. has announced that Health~Holland has awarded a research grant of approximately $375,000 USD to Leiden University Medical Center  and, through a three-party Consortium Agreement, to Acurx Pharmaceuticals. The funding supports the POLSTOP4MDRO project, which aims to assess conservation in the mode-of-action and resistance for a novel class of antimicrobials targeting DNA polymerase pol IIIC. This collaborative initiative will utilize advanced structural biology techniques to further the development of new antibiotics for multidrug-resistant Gram-positive infections. The grant is jointly awarded to both LUMC and Acurx Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL7c66sQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4563","ACXP"],"gpt_icon":0},{"id":"2582911375","title":"Acurx Pharma Q3 net loss narrows to $2 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2582911375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582911375?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:15","pubTimestamp":1762949745,"startTime":"0","endTime":"0","summary":"Acurx Pharma Q3 net loss narrows to $2 mlnOverviewAcurx Q3 net loss narrows to $2 mln, with EPS at -$1.23R&D expenses decreased to $0.4 mln due to lower manufacturing and consulting costsCompany compl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4139","BK4539","BK4563"],"gpt_icon":0},{"id":"2582730753","title":"Acurx Pharmaceuticals reports third quarter cash position of $5.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582730753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582730753?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948932,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. reported a net loss of $2.0 million, or $1.23 per diluted share, for the third quarter ended September 30, 2025, compared to a net loss of $2.8 million, or $3.45 per diluted share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $5.01 per share, compared to $11.3 million, or $14.23 per share, in the prior year period. The company ended the quarter with $5.9 million in cash, up from $3.7 million as of December 31, 2024. General and administrative expenses for the nine months ended September 30, 2025, were $4.9 million, down from $6.8 million for the same period in 2024. Key business developments included the publication of structural biology research on ibezapolstat in Nature Communications, the granting of a new Australian patent for DNA polymerase IIIC inhibitors, and the approval of an increase in authorized common stock from 200 million to 250 million shares. The company had 1,800,299 shares outs","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL4PLYtY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACXP","BK4563","BK4139"],"gpt_icon":0},{"id":"2582732973","title":"Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582732973","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582732973?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948931,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.31) by 6.11 percent. This is a 64.35 percent increase over losses of $(3.45) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48798771/acurx-pharmaceuticals-q3-eps-1-23-beats-1-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","TSYW.SI","MNQmain","SQQQ","PSQ","QID","QLD","TQQQ","USJW.SI","NVIW.SI","BK4139","BK4563","BK4539","USAW.SI","NQmain","ACXP"],"gpt_icon":0},{"id":"2582373226","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373226","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373226?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948860,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include:. -- On August 4, 2025, we effected a 1-for-20 reverse stock split of our. issued and outstanding shares of common stock, and as a result of the. reverse-stock-split, on August 26, 2025, we regained compliance with the. minimum bid price requirement of $1.00 per share under the Nasdaq Listing. Rules.  In addition, we met the minimum stockholders' equity threshold of. $2.5 million under Nasdaq Listing Rules.  We are now in full compliance. with all Nasdaq continued listing requirements and our common stock will. remain listed and traded on the Nasdaq Stock Market.-- In September 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4135","NQmain","R","BK4139","MAA","BK4232","BK4539","GAIN","BK4022","BK4585","BK4588","ACXP","BK4215"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPRT","IMRX","BLDP","ALC","CSCO","ATXS","AYTU","MGX","AFCG","ABOS","AVBP","BABA","BEEM","CELC","AMAT","AKRO","ANNX","ASND","ARCO","ARX","PYPD","CURI","CLBT","ABEO","AIRG","CINT","AFYA","ATAT","CREX","CABA","CCAP","ALUR","RSKD","AEBI","TWFG","ARDT","AEMD","CRMT","CRMD","ABSI","ALVO","IBTA","ALMS","ACXP","ALH","CAAP","GUTS","LUNG","AUTL"],"gpt_icon":1},{"id":"2582187161","title":"Acurx announces publication of results from ibezapolstat study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582187161","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582187161?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:10","pubTimestamp":1762780240,"startTime":"0","endTime":"0","summary":"Acurx (ACXP) Pharmaceuticals announced the publication of results from its scientific collaboration with Leiden University Medical Center, or LUMC,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-announces-publication-of-results-from-ibezapolstat-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-announces-publication-of-results-from-ibezapolstat-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ACXP","BK4563","BK4139"],"gpt_icon":0},{"id":"2582879082","title":"Acurx Reveals Breakthrough DNA pol IIIC Inhibitor Targeting Drug-Resistant Bacteria","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879082","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879082?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:07","pubTimestamp":1762780049,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. has announced the publication of scientific research results from its collaboration with Leiden University Medical Center, revealing for the first time the structure of ibezapolstat, a DNA polymerase IIIC  inhibitor, bound to its bacterial target. The findings, published in Nature Communications, highlight the unique way ibezapolstat selectively targets Gram-positive priority pathogens, including C. difficile, MRSA, VRE, and PRSP. These results build on previously reported Phase 2 clinical efficacy of ibezapolstat in treating C. difficile infection, with a 96% initial cure rate and no recurrence. The new structural insights are already being used to advance the design of next-generation antibiotics against multi-drug-resistant bacteria.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL9V1C2r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","ACXP"],"gpt_icon":0},{"id":"2582879733","title":"Acurx Pharmaceuticals Reports Phase 2 Success for Ibezapolstat in C. difficile Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879733","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879733?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:03","pubTimestamp":1762779824,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. has announced the publication of results from a scientific collaboration with Leiden University Medical Center , detailing structural biology research on its lead antibiotic candidate, ibezapolstat. The study, published in Nature Communications, demonstrates for the first time the binding of ibezapolstat, a DNA pol IIIC inhibitor, to its bacterial target. Ibezapolstat has shown 96% initial cure with no recurrence in Phase 2 clinical trials for C. difficile infection and is now ready for Phase 3 trials in the U.S. and EU. The company is also advancing new DNA pol IIIC inhibitor antibiotics for other multi-drug-resistant Gram-positive pathogens. The results have already been published and presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL6TNVkv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACXP","BK4539","BK4563"],"gpt_icon":0},{"id":"2578959307","title":"Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959307?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:03","pubTimestamp":1761653018,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. has announced new data on its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready candidate ibezapolstat. The results were presented at the Infectious Diseases Society of America  IDWeek 2025 Scientific Conference. The presentation included updates on ibezapolstat's selective antibacterial activity in the gut, which spares beneficial bile acid-metabolizing bacteria and may contribute to reduced recurrence of C. difficile infection. Additionally, new colonic microbiome data from a mouse infection model suggest that microbiome selectivity may be a class effect among DNA pol IIIC inhibitors, when compared to the comparator antibiotic linezolid.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL9Xmndj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACXP","BK4563","BK4139"],"gpt_icon":0},{"id":"2578764569","title":"Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2578764569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578764569?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:00","pubTimestamp":1761566431,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA53PLRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACXP","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2577394899","title":"Acurx files to sell 585,000 shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577394899","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577394899?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:30","pubTimestamp":1760995817,"startTime":"0","endTime":"0","summary":"17:27 EDT Acurx (ACXP) files to sell 585,000 shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mark...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-files-to-sell-585000-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-files-to-sell-585000-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4139","ACXP","BK4539"],"gpt_icon":0},{"id":"2574159074","title":"Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2574159074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574159074?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:31","pubTimestamp":1760009468,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics. Acurx Pharmaceuticals Inc. announced that it has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, including composition-of-matter claims. This patent expands the company's growing international intellectual property portfolio for its ACX-375C program, which targets difficult-to-treat bacterial infections. In addition to the new Australian patent, similar patents have already been granted in the United States, Israel, Japan, and India, with further applications underway in other countries. The company stated that its lead DNA Polymerase IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile infection, while new preclinical compounds are being developed for a range of serious bacterial infections.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL3lSMlD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4563","ACXP"],"gpt_icon":0},{"id":"2573928451","title":"Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928451?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:01","pubTimestamp":1759924882,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks are soaring on Wednesday in what appears to be a continuation of yesterday’s speculative trading for Galecto.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-are-pharmaceutical-stocks-xbio-upc-xtlb-acxp-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-are-pharmaceutical-stocks-xbio-upc-xtlb-acxp-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPC","ACXP","XBIO","BK4539","XTLB","BK4007","BK4139","BK4563"],"gpt_icon":0},{"id":"2573194078","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2573194078","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573194078?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:40","pubTimestamp":1759923611,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences (XBIO) shares were up more than three-fold, or 196%, pre-bell Wednesday, adding to Tuesday's gains.AlphaTON Capital (ATON) stock was up 196% after the company said it entered into ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UPC","XBIO","BK4539","BK4007","ACXP","ATON","BK4139","BK4563"],"gpt_icon":0},{"id":"2571179324","title":"Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2571179324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571179324?lang=en_us&edition=fundamental","pubTime":"2025-09-30 23:20","pubTimestamp":1759245600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2025 11:20 ET (15:20 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2571860344","title":"Acurx Announces Positive Opinion From Ema on Pediatric Investigation Plan for Ibezapolstat Use in Children With C. Difficile Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2571860344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571860344?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:32","pubTimestamp":1759231958,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VH0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","BK4139","ACXP"],"gpt_icon":0},{"id":"2571344845","title":"Acurx Pharmaceuticals Receives Positive EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Children with C. difficile Infection, Advancing Toward Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2571344845","media":"Reuters","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571344845?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:30","pubTimestamp":1759231836,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Receives Positive EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Children with C. difficile Infection, Advancing Toward Phase 3 Trials. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire  on September 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL3GLMmN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACXP","BK4539","BK4563"],"gpt_icon":0},{"id":"2569986711","title":"Acurx Pharmaceuticals Increases Authorized Shares to 250 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2569986711","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569986711?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:26","pubTimestamp":1758641171,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. announced that its stockholders have approved an amendment to the company's Certificate of Incorporation, increasing the total number of authorized shares of common stock from 200 million to 250 million. The amendment was filed with the Secretary of State of Delaware and took effect immediately.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL2CFgGw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","ACXP","BK4539"],"gpt_icon":0},{"id":"2565149795","title":"Acurx Pharmaceuticals Expands Media Partnership with New to The Street for Enhanced Investor Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2565149795","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565149795?lang=en_us&edition=fundamental","pubTime":"2025-09-06 21:55","pubTimestamp":1757166916,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals, Inc. , a biopharmaceutical company focusing on developing new antibiotics for challenging bacterial infections, has renewed its media partnership with New to The Street. The expanded agreement includes long-form televised interviews, national TV commercials, and participation in investor forums, aimed at increasing the company's visibility among investors. The partnership will feature Acurx on platforms such as Bloomberg Television, Fox Business, and social media, as well as providing direct access to accredited investors through exclusive events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on Septem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250906:nNDL27X21k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACXP","BK4539","BK4563"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acurxpharma.com","stockEarnings":[{"period":"1week","weight":-0.0251},{"period":"1month","weight":-0.1954},{"period":"3month","weight":-0.1566},{"period":"6month","weight":-0.6347},{"period":"1year","weight":-0.7862},{"period":"ytd","weight":-0.785}],"compareEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":0.0439},{"period":"3month","weight":0.0406},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1738}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.095374},{"month":2,"riseRate":0,"avgChangeRate":-0.089244},{"month":3,"riseRate":0.25,"avgChangeRate":-0.162505},{"month":4,"riseRate":0.5,"avgChangeRate":0.00047},{"month":5,"riseRate":0.5,"avgChangeRate":-0.04935},{"month":6,"riseRate":0.5,"avgChangeRate":0.118659},{"month":7,"riseRate":0,"avgChangeRate":-0.160175},{"month":8,"riseRate":0.2,"avgChangeRate":-0.087422},{"month":9,"riseRate":0,"avgChangeRate":-0.115354},{"month":10,"riseRate":0.6,"avgChangeRate":0.545147},{"month":11,"riseRate":0.2,"avgChangeRate":-0.181708},{"month":12,"riseRate":0.4,"avgChangeRate":-0.042146}],"exchange":"NASDAQ","name":"Acurx Pharmaceuticals, LLC*","nameEN":"Acurx Pharmaceuticals, LLC*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acurx Pharmaceuticals, LLC*,ACXP,Acurx Pharmaceuticals, LLC*股票,Acurx Pharmaceuticals, LLC*股票老虎,Acurx Pharmaceuticals, LLC*股票老虎国际,Acurx Pharmaceuticals, LLC*行情,Acurx Pharmaceuticals, LLC*股票行情,Acurx Pharmaceuticals, LLC*股价,Acurx Pharmaceuticals, LLC*股市,Acurx Pharmaceuticals, LLC*股票价格,Acurx Pharmaceuticals, LLC*股票交易,Acurx Pharmaceuticals, LLC*股票购买,Acurx Pharmaceuticals, LLC*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction